Neuland Laboratories

NEULANDLAB.NSPre-clinical

Hyderabad, IndiaFounded 1984neulandlabs.com

Neuland Laboratories is a publicly listed, revenue-generating CDMO focused on providing end-to-end API services from development to commercial-scale manufacturing. The company has established itself as a trusted partner for innovator and generic pharmaceutical companies, with a strong track record in complex chemistry and regulatory compliance across major markets. Its strategic direction involves expanding its capabilities in high-potency APIs (HPAPIs), peptides, and other niche technologies to capitalize on the growing trend of outsourcing in the pharma industry.

Market Cap

$61.1M

Founded

1984

Employees

2000-2500

Focus

Small MoleculesAntibodiesDrug Delivery

NEULANDLAB.NS · Stock Price

USD 454.70+27.40 (+6.41%)

Historical price data

AI Company Overview

Technology Platform

Advanced chemical synthesis and manufacturing platform for Active Pharmaceutical Ingredients (APIs), specializing in complex chemistry, High-Potency APIs (HPAPIs), peptides, and providing end-to-end CDMO services from development to commercial supply.

Funding History

Total raised: $35M

Debt$20MState Bank of IndiaMay 15, 2021

IPO$15MUndisclosedJun 15, 1994

Opportunities

Significant growth opportunities exist in the expanding global CDMO market, particularly in high-value segments like HPAPIs and peptides.

The company can leverage its strong regulatory track record to win more business from innovator pharma companies looking to outsource complex API manufacturing.

Further geographic expansion and deepening service integration present additional avenues for growth.

Risk Factors

Key risks include regulatory compliance challenges at its manufacturing sites, potential loss of major CDMO clients, pricing erosion in the generic API segment, and foreign exchange volatility impacting financial results.

Geopolitical issues affecting global trade could also disrupt supply chains.

Competitive Landscape

Neuland competes with large Indian API/CDMOs like Divi's Labs and Laurus Labs, as well as global giants like Lonza and Catalent. Its differentiation is built on deep expertise in complex chemical synthesis, a fully integrated service model from development to commercial supply, and a strong focus on strategic, long-term client partnerships within the niche of complex molecules.

Publications

Patents